On the stock market since 2014, it operates in the world of health and science. It has 166 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 84% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 72% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 62% a year on average.
Sales run at $15.3M a year. A small number, but proof the product has real buyers.
There is $108.5M in the vault; even if every debt were paid off, $92.1M would remain.
A loss of $40.5M against $15.3M in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, PRQR sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: PRQR is a high-risk stock — not yet profitable, and its future rides on its product catching on.